Semaglutide vs Tirzepatide
Both are once-weekly incretin therapies for weight and glycemic management. Semaglutide is a GLP-1 receptor agonist; tirzepatide is a dual GIP and GLP-1 receptor agonist.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Brands | Ozempic, Wegovy, Rybelsus (oral) | Mounjaro, Zepbound |
| Dosing | Once weekly SC, plus a daily oral option | Once weekly SC |
| Head-to-head weight loss | Lower than tirzepatide in SURMOUNT-5 | Greater than semaglutide in SURMOUNT-5 |
| Track record | Longer real-world history; cardiovascular-outcomes data | Newer; strong trial efficacy |
Lean toward Semaglutide when
- You want the longest real-world track record
- An oral option (Rybelsus) matters to you
- Established cardiovascular-outcomes evidence is a priority
Lean toward Tirzepatide when
- Maximum average weight loss is the priority
- You tolerate the dual-agonist GI profile
Verdict
Both are highly effective. In the head-to-head SURMOUNT-5 phase 3 trial, tirzepatide produced greater weight loss than semaglutide; semaglutide offers a longer track record and an oral formulation. The right choice is individual and a clinician decision. Educational only.
Sources
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.